Company Overview and News

 
H2O Innovation : Piedmont obtient d’importantes commandes et dévoile de nouveaux produits

2018-10-11 globenewswire
QUÉBEC, Québec, 11 oct. 2018 (GLOBE NEWSWIRE) -- (TSXV : HEO) – H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d’annoncer que sa filiale indépendante Piedmont, leader mondial dans l’équipement anticorrosif pour les usines de dessalement pour les marchés industriels et municipaux, a récemment obtenu d’importantes commandes pour ses gammes de produits de raccords flexibles et de filtres à cartouches faits de FRP.
HEOFF ALHEO HEO

 
H2O Innovation: Piedmont Secures Large Orders and Releases New Products

2018-10-11 globenewswire
QUEBEC CITY, Quebec, Oct. 11, 2018 (GLOBE NEWSWIRE) -- (TSXV: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is proud to announce its independent subsidiary, Piedmont, a global leader in corrosion resistant equipment for desalination plants in the industrial and municipal markets, recently secured large orders for its coupling and FRP cartridge filter housing product lines. In addition, Piedmont developed and released new products.
HEOFF ALHEO HEO

 
H2O Innovation : Piedmont obtient d'importantes commandes et dévoile de nouveaux produits

2018-10-11 globenewswire
Québec, le 11 octobre 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d'annoncer que sa filiale indépendante Piedmont, leader mondial dans l'équipement anticorrosif pour les usines de dessalement pour les marchés industriels et municipaux, a récemment obtenu d'importantes commandes pour ses gammes de produits de raccords flexibles et de filtres à cartouches faits de FRP.
HEOFF ALHEO HEO

 
H2O Innovation: Piedmont Secures Large Orders and Releases New Products

2018-10-11 globenewswire
Quebec City, October 11, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") is proud to announce its independent subsidiary, Piedmont, a global leader in corrosion resistant equipment for desalination plants in the industrial and municipal markets, recently secured large orders for its coupling and FRP cartridge filter housing product lines. In addition, Piedmont developed and released new products.
HEOFF ALHEO HEO

 
H2O Innovation lance son nouveau produit préassemblé de traitement d’eaux usées à WEFTEC

2018-10-02 globenewswire
QUÉBEC, 02 oct. 2018 (GLOBE NEWSWIRE) -- (TSXV : HEO) – H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière de lancer cette semaine son nouveau produit préassemblé de traitement d’eaux usées, le SILO, à WEFTEC (la plus importante conférence et exposition technique annuelle sur la qualité de l'eau) en Nouvelle-Orléans.
HEOFF ALHEO HEO

 
H2O Innovation Releases its New Packaged Wastewater Treatment Product at WEFTEC

2018-10-02 globenewswire
QUEBEC CITY, Oct. 02, 2018 (GLOBE NEWSWIRE) -- (TSXV: HEO) – H2O Innovation Inc. (“H2O Innovation” or the “Corporation”) is proud to release its new packaged wastewater treatment product, the SILO, during this week’s WEFTEC (World’s largest annual water quality technical conference and exhibition) in New Orleans.
HEOFF ALHEO HEO

 
H2O Innovation Releases its New Packaged Wastewater Treatment Product at WEFTEC

2018-10-02 globenewswire
Quebec City, October 2, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") is proud to release its new packaged wastewater treatment product, the SILO, during this week's WEFTEC (World's largest annual water quality technical conference and exhibition) in New Orleans.
HEOFF ALHEO HEO

 
H2O Innovation lance son nouveau produit préassemblé de traitement d'eaux usées à WEFTEC

2018-10-02 globenewswire
Québec, le 2 octobre 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière de lancer cette semaine son nouveau produit préassemblé de traitement d'eaux usées, le SILO, à WEFTEC (la plus importante conférence et exposition technique annuelle sur la qualité de l'eau) en Nouvelle-Orléans.
HEOFF ALHEO HEO

 
Sustained organic revenue growth of 20.4% and improvement of the adjusted EBITDA performance by 125.4% compared to previous fiscal year

2018-09-26 globenewswire
Quebec City, September 26, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") announces its results for the fourth quarter and fiscal year ended June 30, 2018. H2O Innovation's revenues for fiscal year 2018 increased by 20.4 % to reach $99.7 M, up from revenues of $82.8 M for fiscal year 2017, generating a gross profit margin before depreciation and amortization of $22.
HEOFF ALHEO HEO

 
Croissance organique soutenue des revenus de 20,4 % et amélioration de la performance du BAIIA ajusté de 125,4% par rapport à l'exercice financier précédent

2018-09-26 globenewswire
Québec, le 26 septembre 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») fait connaître aujourd'hui ses résultats du quatrième trimestre ainsi que de l'exercice financier terminé le 30 juin 2018. Les revenus de l'exercice financier 2018 ont augmenté de 20,4 % pour atteindre 99,7 M $, en hausse par rapport aux revenus de 82,8 M $ pour l'année financière précédente, générant une marge bénéficiaire brute avant amortissements de 22,1 M $.
HEOFF ALHEO HEO

 
H2O Innovation will release its financial results for the fourth quarter and full fiscal year of 2018

2018-09-12 globenewswire
Quebec City, September 12, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") announces that it will release its financial results for the fourth quarter and full fiscal year ended on June 30, 2018 on Wednesday, September 26, 2018, at approximately 2:00 p.m. Paris Time (8:00 a.m. Eastern Time). The Corporation will also host a conference call, on the same day, at 4:00 p.
HEOFF ALHEO HEO

 
H2O Innovation annonce la publication de ses résultats financiers du quatrième trimestre et de l'année financière 2018

2018-09-12 globenewswire
Québec, le 12 septembre 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») annonce aujourd'hui qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année financière terminés le 30 juin 2018, le mercredi 26 septembre 2018, vers 14h00, heure de Paris (8h00 HAE). La Société tiendra également une conférence téléphonique, le jour même, à 16h00 heure de Paris (10h00 HAE).
HEOFF ALHEO HEO

 
H2O Innovation : Utility Partners renouvelle deux contrats d'O&M, totalisant 24,3 M $

2018-09-11 globenewswire
Québec, le 11 septembre 2018 - (TSXV : HEO) - H2O Innovation inc. (« H2O Innovation » ou la « Société ») est fière d'annoncer qu'Utility Partners, LLC (« UP »), son unité d'affaires dédiée aux services d'opération et maintenance (« O&M ») aux États-Unis, a récemment renouvelé deux contrats d'O&M venant à échéance. Ces contrats, d'une valeur totale de 24,3 M $, portent le carnet de commandes d'O&M à 89,1 M $.
HEOFF ALHEO HEO

 
H2O Innovation: Utility Partners Renews Two O&M Contracts, totaling $24.3 M

2018-09-11 globenewswire
Quebec City, September 11, 2018 - (TSXV: HEO) - H2O Innovation Inc. ("H2O Innovation" or the "Corporation") is proud to announce that Utility Partners, LLC ("UP"), its business line providing operation and maintenance services ("O&M") in the United States, recently renewed two contracts. These contracts, valued at $24.3 M, bring the Corporation's O&M business backlog to $89.1 M.
HEOFF ALHEO HEO

 
H2O Innovation : Utility Partners remporte un nouveau projet et renouvelle un contrat existant, totalisant 10,1 M $

2018-07-25 globenewswire
QUÉBEC, 25 juill. 2018 (GLOBE NEWSWIRE) -- H2O Innovation inc. (TSX CROISSANCE:HEO) (« H2O Innovation » ou la « Société ») est fière d’annoncer qu’Utility Partners, LLC (« UP »), son unité d’affaires dédiée aux services d’opération et maintenance (« O&M ») aux États-Unis, a récemment remporté un nouveau projet d’O&M et a renouvelé un contrat venant à échéance. Ces contrats, d’une valeur totale de 10,1 M $, portent le carnet de commandes d’O&M à 71,3 M $.
HEOFF ALHEO HEO

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...